NCCM
ITCI icon

Nine Chapters Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nine Chapters Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,200
Closed -$166K – 187
2017
Q1 		$166K Buy
+10,200
New +$148K 0.22% 175

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Nine Chapters Capital Management's ITCI Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 10,200 shares — an estimated $166K sold.

Nine Chapters Capital Management first reported a position in ITCI in Q1 2017 and held it in 1 quarter. The position peaked at $166K in Q1 2017. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 10,200 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $166K.
  • Nine Chapters Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's Intra-Cellular Therapies Inc. position peaked at $166K in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.